CTI BioPharma provides update on investigational agent pacritinib
CTI BioPharma announced the Company received written communication from the FDA Feb. 4, 2016, that the FDA has placed a partial clinical hold on the clinical studies being conducted under the Company's IND application for pacritinib. February 08, 2016